EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis

Lukas E Brümmer iD, Ryan R Thompson, Akash Malhotra, Sourya Shrestha, Emily A Kendall, Jason R Andrews, Patrick Phillips, Payam Nahid, Adithya Cattamanchi, Florian M Marx, Claudia M Denkinger, David W Dowdy

Clinical Infectious Diseases · 25.01.2024 · 78 (1) · 154-163

DOI: 10.1093/cid/ciad501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.08.2023. Verfasst von Lukas E Brümmer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Tuberculosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, German Centre for Infection Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In high-burden settings, low-complexity screening tests for tuberculosis (TB) could expand the reach of community-based case-finding efforts. The potential costs and cost-effectiveness of approaches incorporating these tests are poorly understood.

Methods

We developed a microsimulation model assessing 3 approaches to community-based case-finding in hypothetical populations (India-, South Africa-, The Philippines-, Uganda-, and Vietnam-like settings) with TB prevalence 4 times that of national estimates: (1) screening with a point-of-care C-reactive protein (CRP) test, (2) screening with a more sensitive “Hypothetical Screening test” (95% sensitive for Xpert Ultra-positive TB, 70% specificity; equipment/labor costs similar to Xpert Ultra, but using a $2 cartridge) followed by sputum Xpert Ultra if positive, or (3) testing all individuals with sputum Xpert Ultra. Costs are expressed in 2023 US dollars and include treatment costs.

Results

Universal Xpert Ultra was estimated to cost a mean $4.0 million (95% uncertainty range: $3.5 to $4.6 million) and avert 3200 (2600 to 3900) TB-related disability-adjusted life years (DALYs) per 100 000 people screened ($670 [The Philippines] to $2000 [Vietnam] per DALY averted). CRP was projected to cost $550 (The Philippines) to $1500 (Vietnam) per DALY averted but with 44% fewer DALYs averted. The Hypothetical Screening test showed minimal benefit compared to universal Xpert Ultra, but if specificity were improved to 95% and per-test cost to $4.5 (all-inclusive), this strategy could cost $390 (The Philippines) to $940 (Vietnam) per DALY averted.

Conclusions

Screening tests can meaningfully improve the cost-effectiveness of community-based case-finding for TB but only if they are sensitive, specific, and inexpensive.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisHumansCost-Benefit AnalysisSouth AfricaHealth Care CostsSputumSensitivity and Specificity

Stichwörter der Autor:innen

cost-effectivenessdiagnosticsmathematical modellingscreeningtuberculosis

Autor:innen und Institutionen

  • Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • German Center for Infection Research (DZIF), partner site Heidelberg, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, San Francisco, California, USA.
  • Center for Tuberculosis, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, California, USA.

ORCID-Profile: Lukas E Brümmer

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • German Centre for Infection Research
  • US National Institutes of Health
  • National Institute of Allergy and Infectious Diseases, Continuation
  • NIH

Zitieren

APA

Brümmer, L. E., Thompson, R. R., Malhotra, A., Shrestha, S., Kendall, E. A., Andrews, J. R., Phillips, P., Nahid, P., Cattamanchi, A., Marx, F. M., Denkinger, C. M., & Dowdy, D. W. (2024). Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis. Clinical Infectious Diseases, 78(1), 154-163. https://doi.org/10.1093/cid/ciad501

Vancouver

Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, et al. Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis. Clinical Infectious Diseases. 2024;78(1):154-163. doi:10.1093/cid/ciad501

BibTeX
@article{Brmmer2024,
  author = {Brümmer, Lukas E and Thompson, Ryan R and Malhotra, Akash and Shrestha, Sourya and Kendall, Emily A and Andrews, Jason R and Phillips, Patrick and Nahid, Payam and Cattamanchi, Adithya and Marx, Florian M and Denkinger, Claudia M and Dowdy, David W},
  title = {Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {1},
  pages = {154--163},
  doi = {10.1093/cid/ciad501}
}
Kostenlos starten →